Measurement of exhaled nitric oxide concentration in asthma: A systematic review and economic evaluation of NIOX MINO, NIOX VERO and Nobreath

Health Technology Assessment

Volumn 19, Issue 82, 2015, Pages 1-330

  Harnan, Sue E ^a   Tappenden, Paul ^a   Essat, Munira ^a   Gomersall, Tim ^a   Minton, Jon ^b   Wong, Ruth ^a   Pavord, Ian ^c   Everard, Mark ^d   Lawson, Rod ^e  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; NITRIC OXIDE;

ARTICLE; ASTHMA; CHEMOLUMINESCENCE; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; ECONOMIC EVALUATION; EXPIRED AIR; FRACTION OF EXHALED NITRIC OXIDE; HUMAN; METHACHOLINE CHALLENGE TEST; NITRIC OXIDE ANALYZER; PASSIVE SMOKING; PREDICTIVE VALUE; PREGNANT WOMAN; QUALITY ADJUSTED LIFE YEAR; REFERENCE VALUE; RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT EXAMINATION; SENSITIVITY AND SPECIFICITY; SMOKING; SYSTEMATIC REVIEW; BIOMEDICAL TECHNOLOGY ASSESSMENT; BREATH ANALYSIS; COST BENEFIT ANALYSIS; DEVICES; DISEASE MANAGEMENT; ECONOMIC MODEL; ECONOMICS; LUMINESCENCE;

ADRENAL CORTEX HORMONES; ASTHMA; BREATH TESTS; COST-BENEFIT ANALYSIS; DISEASE MANAGEMENT; HUMANS; LUMINESCENT MEASUREMENTS; MODELS, ECONOMIC; NITRIC OXIDE; QUALITY-ADJUSTED LIFE YEARS; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84945308673     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta19820     Document Type: Article

References (193)

1. de Roberto M, Locatelli F, Sunyer J, Burney P. Differences in incidence of reported asthma related to age in men and women. Am J Respir Crit Care Med 2000;162:68-74. http://dx.doi.org/10.1164/ajrccm.162.1.9907008
2. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360:1715-21. http://dx.doi.org/10.1016/S0140-6736(02)11679-5
3. Wardlaw A, Brightling C, Green R, Woltmann G, Pavord I. Eosinophils in asthma and other allergic diseases. Br Med Bull 2000;56:985-1003. http://dx.doi.org/10.1258/0007142001903490
4. Berry M, Morgan A, Shaw D, Parker D, Green R, Brightling C, et al. Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax 2007;62:1043-9. http://dx.doi.org/10.1136/thx.2006.073429
5. Schleich FN, Seidel L, Sele J, Manise M, Quaedvlieg V, Michils A, et al. Exhaled nitric oxide thresholds associated with a sputum eosinophil count ≥ 3% in a cohort of unselected patients with asthma. Thorax 2010;65:1039-44. http://dx.doi.org/10.1136/thx.2009.124925
6. Pavord ID, Shaw DE, Gibson PG, Taylor DR. Inflammometry to assess airway diseases. Lancet 2008;372:1017-19. http://dx.doi.org/10.1016/S0140-6736(08)61421-X
7. Sur S, Crotty T, Kephart G, Hyma B, Colby T, Reed C, et al. Sudden-onset fatal asthma: a distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa? Am Rev Respir Dis 1993;148:713-19. http://dx.doi.org/10.1164/ajrccm/148.3.713
8. British Thoracic Society/Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma: a National Clinical Guideline. Edinburgh and London: BTS/SIGN; 2012.
9. Wenzel S. Asthma phenotypes: the evolution from clinical to molecular approaches. Nature Med 2012;18:716-25. http://dx.doi.org/10.1038/nm.2678
10. Gotshall R. Exercise-induced bronchoconstriction. Drugs 2002;62:1725-39. http://dx.doi.org/10.2165/00003495-200262120-00003
11. Anderson H, Gupta R, Strachan D, Limb E. 50 years of asthma: UK trends from 1955 to 2004. Thorax 2007;62:85-90. http://dx.doi.org/10.1136/thx.2006.066407
12. Hall J, Mindell J. Health Survey for England 2010: Volume 1. Chapter 2: Respiratory Symptoms and Disease in Adults. Leeds: Health & Social Care Information Centre; 2011. URL: www.hscic.gov.uk/catalogue/PUB03023/heal-surv-eng-2010-resp-heal-ch2-symp-adul.pdf (accessed 21 May 2015).
13. Shepherd J, Rogers G, Anderson R, Main C, Thompson-Coon J, Hartwell D, et al. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over. Health Technol Assess 2008;12(19). http://dx.doi.org/10.3310/hta12190
14. Burr M, Davies B, Hoare A, Jones A, Williamson I, Holgate S, et al. A confidential inquiry into asthma deaths in Wales. Thorax 1999;54:985-9. http://dx.doi.org/10.1136/thx.54.11.985
15. Bucknall C, Slack R, Godley C, Mackay T, Wright S. Scottish Confidential Inquiry into Asthma Deaths (SCIAD), 1994-6. Thorax 1999;54:984. http://dx.doi.org/10.1136/thx.54.11.978
16. Sturdy P, Victor C, Anderson H, Bland J, Butland B, Harrison B, et al. Psychological, social and health behaviour risk factors for deaths certified as asthma: a national case-control study. Thorax 2002;57:1034-9. http://dx.doi.org/10.1136/thorax.57.12.1034
17. Sturdy P, Butland B, Anderson H, Ayres JG, Bland J, Harrison B, et al. Deaths certified as asthma and use of medical services: a national case-control study. Thorax 2005;60:909-15. http://dx.doi.org/10.1136/thx.2004.025593
18. Jones K, Berrill W, Bromly C, Hendrick D. A confidential enquiry into certified asthma deaths in the North of England, 1994-96: influence of co-morbidity and diagnostic inaccuracy. Respir Med 1999;93:923-7. http://dx.doi.org/10.1016/S0954-6111(99)90061-6
19. Brown P, Greville H, Finucane K. Asthma and irreversible airflow obstruction. Thorax 1984;39:131-6. http://dx.doi.org/10.1136/thx.39.2.131
20. Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000;343:1054-63. http://dx.doi.org/10.1056/NEJM200010123431501
21. Agertoft L, Pederson S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 2000;343:1064-9. http://dx.doi.org/10.1056/NEJM200010123431502
22. Craig R, Mindell J. Health Survey for England 2010: Volume 1 - Respiratory Health. NHS Information Centre. Leeds: Health and Social Care Information Centre; 2011. URL: www.hscic. gov.uk/catalogue/PUB03023/heal-surv-eng-2010-resp-heal-summ-rep.pdf (accessed September 2015).
23. Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011;184:602-15. http://dx.doi.org/10.1164/rccm.9120-11ST
24. Kostikas K, Minas M, Papaioannou AI, Papiris S, Dweik RA. Exhaled nitric oxide in asthma in adults: the end is the beginning? Curr Med Chem 2011;18:1423-31. http://dx.doi.org/10.2174/ 092986711795328436
25. Jatakanon A, Kharitonov S, Lim S, Barnes PJ. Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma. Thorax 1999;54:108-14. http://dx.doi.org/10.1136/thx.54.2.108
26. Jones SL, Herbison P, Cowan JO, Flannery EM, Hancox RJ, McLachlan CR, et al. Exhaled NO and assessment of anti-inflammatory effects of inhaled steroid: dose-response relationship. Eur Respir J 2002;20:601-8. http://dx.doi.org/10.1183/09031936.02.00285302
27. Silkoff PE, McClean P, Spino M, Erlich L, Slutsky AS, Zamel N, et al. Dose-response relationship and reproducibility of the fall in exhaled nitric oxide after inhaled beclomethasone dipropionate therapy in asthma patients. Chest 2001;119:1322-8. http://dx.doi.org/10.1378/chest.119.5.1322
28. Aerocrine. Stakeholders Comments to NICE. URL: www.nice.org.UK/Nicemedia/Live/13864/65621/65621 Pdf. 2013 (accessed 23 April 2014).
29. National Institute for Health and Care Excellence. Measurement of Exhaled Nitric Oxide Concentration in Asthma; NIOX MINO and NObreath. Final Scope. London: NICE; 2013.
30. Minton J, Harnan S, Essat M, Wong R, Tappenden P. Measurement of Exhaled Nitric Oxide Concentration in Asthma: NIOX MINO and NObreath. PROSPERO 2013:CRD42013004149. URL: www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42013004149 (accessed 21 July 2015).
31. Petsky HL, Cates CJ, Li A, Kynaston JA, Turner C, Chang AB. Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults. Cochrane Database Syst Rev 2009;4:CD006340. http://dx.doi.org/10.1002/14651858.cd006340.pub3
32. Jartti T, Wendelin-Saarenhovi M, Heinonen I, Hartiala J, Vanto T. Childhood asthma management guided by repeated FeNO measurements: a meta-analysis. Paediatr Respir Rev 2012;13:178-83. http://dx.doi.org/10.1016/j.prrv.2011.11.002
33. Spahn AJD, Malka J, Mahr TA, Dorinsky PM. Meta analysis of asthma exacerbation rates in pediatric studies during asthma managed using fractional exhaled nitric oxide versus standard clinical parameters. J Allergy Clin Immunol 2013;131(Suppl. 1):AB194. http://dx.doi.org/10.1016/j.jaci.2012.12.1362
34. National Institute for Health and Care Excellence. Clinical Guideline Development Methods. London: NICE; 2012.
35. American Thoracic Society, European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide. Am J Respir Crit Care Med 2005;171:912-30. http://dx.doi.org/10.1164/rccm.200406-710ST
36. Higgins J, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. [updated March 2011]. The Cochrane Collaboration; 2011. URL: www.cochrane-handbook.org (accessed 21 July 2015).
37. Centre for Reviews and Dissemination. Systematic Reviews - CRD’s Guidance for Undertaking Reviews in Healthcare. York: Centre for Reviews and Dissemination, University of York; 2009.
38. Whiting P, Rutjes A, Westwood M, Mallett S, Deeks J, Reitsma J, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529-36. http://dx.doi.org/10.7326/0003-4819-155-8-201110180-00009
39. Menzies D, Nair A, Lipworth BJ. Portable exhaled nitric oxide measurement: comparison with the ‘gold standard’ technique. Chest 2007;131:410-14. http://dx.doi.org/10.1378/chest.06-1335
40. Grob NM, Laskowski D, Dweik RA. A technical report on exhaled nitric oxide measurement: asthma monitoring in athletes. J Breath Res 2008;2:37027. http://dx.doi.org/10.1088/1752-7155/2/3/037027
41. Korn S, Telke I, Kornmann O, Buhl R. Measurement of exhaled nitric oxide: comparison of different analysers. Respirology 2010;15:1203-8. http://dx.doi.org/10.1111/j.1440-1843.2010.01847.x
42. Chen W, Purohit A, Barnig C, Casset A, de Blay F. Niox and Niox Mino: comparison of exhaled NO in grass pollen allergic adult volunteers. Allergy 2007;62:571-2. http://dx.doi.org/10.1111/ j.1398-9995.2007.01334.x
43. Hemmingsson T, Linnarsson D, Gambert R. Novel hand-held device for exhaled nitric oxide-analysis in research and clinical applications. J Clin Monit Comput 2004;18:379-87. [Erratum published in J Clin Monit Comput 2005;19:463-4]. http://dx.doi.org/10.1007/s10877-005-1158-z
44. Pizzimenti S, Bugiani M, Piccioni P, Heffler E, Carosso A, Guida G, et al. Exhaled nitric oxide measurements: correction equation to compare hand-held device to stationary analyzer. Respir Med 2008;102:1272-5. http://dx.doi.org/10.1016/j.rmed.2008.04.006
45. Khalili B, Boggs PB, Bahna SL. Reliability of a new hand-held device for the measurement of exhaled nitric oxide. Allergy 2007;62:1171-4. http://dx.doi.org/10.1111/j.1398-9995.2007.01475.x.
46. Alving K, Janson C, Nordvall L. Performance of a new hand-held device for exhaled nitric oxide measurement in adults and children. Respir Res 2006;7:67. http://dx.doi.org/10.1186/1465-9921-7-67
47. Vahlkvist S, Sinding M, Skamstrup K, Bisgaard H. Daily home measurements of exhaled nitric oxide in asthmatic children during natural birch pollen exposure. J Allergy Clin Immunol 2006;117:1272-6. http://dx.doi.org/10.1016/j.jaci.2006.03.018
48. McGill C, Malik G, Turner SW. Validation of a hand-held exhaled nitric oxide analyzer for use in children. Pediatr Pulmonol 2006;41:1053-7. http://dx.doi.org/10.1002/ppul.20491
49. Kalliola S, Malmberg P, Rito T, Pelkonen AS, Makela MJ. Can we use portable nitric oxide analyzer in young children? Pediatr Pulmonol 2011;46:627-31. http://dx.doi.org/10.1002/ppul.21390
50. Ozier A, Girodet PO, Marthan R, Berger P. Reliability of the hand-held NIOX MINO device for monitoring asthma control. Fund Clin Pharmacol 2010;24:105.
51. Ozier A, Girodet P-O, Bara I, Tunon de Lara JM, Marthan R, Berger P. Control maintenance can be predicted by exhaled NO monitoring in asthmatic patients. Respir Med 2011;105:989-96. http://dx.doi.org/10.1016/j.rmed.2011.01.006
52. Fortuna AM, Fexias T, Gonzalez M, Casan P. Determination of exhaled nitric oxide in healthy volunteers and asthmatic patients - comparison of two devices. Eur Respir J 2006;28:791s.
53. Fortuna AM, Feixas T, Casan P. [Measurement of fraction of exhaled nitric oxide with the portable NIOX-MINO monitor in healthy adults]. Arch Bronconeumol 2007;43:176-9. http://dx.doi.org/10.1016/S1579-2129(07)60044-5
54. Fukuhara A, Saito J, Sato S, Sato Y, Nikaido T, Saito K, et al. Validation study of asthma screening criteria based on subjective symptoms and fractional exhaled nitric oxide. Ann Allergy Asthma Immunol 2011;107:480-6. http://dx.doi.org/10.1016/j.anai.2011.09.002
55. Kim SH, Moon JY, Kwak HJ, Kim SI, Park DW, Kim JW, et al. Comparison of two exhaled nitric oxide analyzers: the NIOX MINO hand-held electrochemical analyzer and the NOA280i stationary chemiluminescence analyzer. Respirol 2012;17:830-4. http://dx.doi.org/10.1111/j.1440-1843.2012.02163.x
56. Yoon H, Kwak H, Kim T, Sohn J, Shin D, Park S, et al. Measurement of exhaled nitric oxide: comparison of two analyzers. Allergy 2011;66:535. http://dx.doi.org/10.1111/j.1440-1843.2012.02163.x
57. de Laurentiis G, Maniscalco M, Cianciulli F, Stanziola A, Marsico S, Lundberg JO, et al. Exhaled nitric oxide monitoring in COPD using a portable analyzer. Pulm Pharmacol Ther 2008;21:689-93. http://dx.doi.org/10.1016/j.pupt.2008.04.006
58. Peche R, Michils A, Baldassarre S, Mourid Z, Muylem A. Exhaled nitric oxide measured by using NIOX MINO and chemo-luminesence analyser: a comparative study. Eur Respir J 2007;30:365s.
59. Michils A, Peche R, Baldassarre S, Mourid Z, Van MA. Comparisons between portable and chemoluminescence exhaled nitric oxide measurements. Eur Respir J 2008;32:243-4. http://dx.doi.org/10.1183/09031936.00025308
60. Logan Research Ltd. Benchmark Testing Report. Comparison Testing Carried Out by Logan Fesearch Ltd for Bedfont Scientific Ltd - Reference the NObreath Nitric Oxide Monitoring Product. Internal report supplied by Bedfont (manufacturers), Rochester; 2009.
61. Park YA, Lee JH, Lee YJ, Song TW, Kim KW, Sohn MH, et al. Comparison of exhaled nitric oxide analysers in childhood asthma. J Allergy Clin Immunol 2011;127(Suppl. 1):AB62. http://dx.doi.org/10.1016/j.jaci.2010.12.258
62. Schiller B, Hammer J, Barben J, Trachsel D. Comparability of a hand-held nitric oxide analyser with online and offline chemiluminescence-based nitric oxide measurement. Pediatr Allergy Immunol 2009;20:679-85. http://dx.doi.org/10.1111/j.1399-3038.2009.00853.x
63. Chladkova J, Havlinova Z, Chyba T, Krcmova I, Chladek J. Analysis of single-breath profiles of exhaled nitric oxide in children with allergy and asthma: guideline-derived plateau concentrations compared to results of automatic evaluation by two analyzers. J Asthma 2008;45:820-6. http://dx.doi.org/10.1080/02770900802312582
64. Boot J, de Ridder L, de Kam M, Calderon C, Mascelli M, Diamant Z. Comparison of exhaled nitric oxide measurements between Niox Mino electrochemical and Ecomedics chemiluminescence analyzer. Respir Med 2008;102:1667-71. http://dx.doi.org/10.1016/j.rmed.2008.06.021
65. Pisi R, Aiello M, Tzani P, Marangio E, Olivieri D, Chetta A, et al. Measurement of fractional exhaled nitric oxide by a new portable device: comparison with the standard technique. J Asthma 2010;47:805-9. http://dx.doi.org/10.3109/02770903.2010.485667
66. Antus B, Horvath I, Barta I. Assessment of exhaled nitric oxide by a new hand-held device. Respir Med 2010;104:1377-80. http://dx.doi.org/10.1016/j.rmed.2010.06.005
67. Kapande KM, McConaghy LA, Douglas I, McKenna S, Hughes JL, McCance DR, et al. Comparative repeatability of two handheld fractional exhaled nitric oxide monitors. Pediatr Pulmonol 2012;47:546-50. http://dx.doi.org/10.1002/ppul.21591
68. Kapande KM, Shields MD, McConaghy LA. Comparative repeatability of two handheld fractional exhaled nitric oxide monitors. Ir J Med Sci 2011;180:S460. http://dx.doi.org/10.1002/ppul.21591
69. Schneider A, Schwarzbach J, Faderl B, Welker L, Karsch-Volk M, Jorres RA. FENO measurement and sputum analysis for diagnosing asthma in clinical practice. Respir Med 2013;107:209-16. http://dx.doi.org/10.1016/j.rmed.2012.10.003
70. Fortuna AM, Feixas T, Gonzalez M, Casan P. Diagnostic utility of inflammatory biomarkers in asthma: exhaled nitric oxide and induced sputum eosinophil count. Respir Med 2007;101:2416-21. [Erratum published in Respir Med 2012;106:599]. http://dx.doi.org/10.1016/j.rmed.2007.05.019
71. Schneider A, Tilemann L, Schermer T, Gindner L, Laux G, Szecsenyi J, et al. Diagnosing asthma in general practice with portable exhaled nitric oxide measurement - results of a prospective diagnostic study. Respir Res 2009;10:15. http://dx.doi.org/10.1186/1465-9921-10-15
72. Schneider A, Tilemann L, Schermer T, Gindner L, Laux G, Szecsenyi J, et al. Diagnosing asthma in general practice with portable exhaled nitric oxide measurement - results of a prospective diagnostic study: FENO ≤ 16 ppb better than FENO ≤ 12 ppb to rule out mild and moderate to severe asthma. Respir Res 2009;10:64. http://dx.doi.org/10.1186/1465-9921-10-64
73. Hsu JY, Wang CY, Cheng YW, Chou MC. Optimal value of fractional exhaled nitric oxide in inhaled corticosteroid treatment for patients with chronic cough of unknown cause. J Chin Med Assoc 2013;76:15-19. http://dx.doi.org/10.1016/j.jcma.2012.08.010
74. Hahn PY, Morgenthaler TI, Lim KG. Use of exhaled nitric oxide in predicting response to inhaled corticosteroids for chronic cough. Mayo Clin Proc 2007;82:1350-5. http://dx.doi.org/10.4065/82.11.1350
75. Sato S, Saito J, Sato Y, Ishii T, Xintao W, Tanino Y, et al. Clinical usefulness of fractional exhaled nitric oxide for diagnosing prolonged cough. Respir Med 2008;102:1452-9. http://dx.doi.org/10.1016/j.rmed.2008.04.018
76. Prieto L, Ferrer A, Ponce S, Palop J, Marin J. Exhaled nitric oxide measurement is not useful for predicting the response to inhaled corticosteroids in subjects with chronic cough. Chest 2009;136:816-22. http://dx.doi.org/10.1378/chest.08-2942.
77. Schleich FN, Asandei R, Manise M, Sele J, Seidel L, Louis R. Is FENO50 useful diagnostic tool in suspected asthma? Int J Clin Pract 2012;66:158-65. http://dx.doi.org/10.1111/j.1742-1241.2011.02840.x
78. El Halawani SM, Ly NT, Mahon RT, Amundson DE. Exhaled nitric oxide as a predictor of exercise-induced bronchoconstriction. Chest 2003;124:639-43. http://dx.doi.org/10.1378/chest.124.2.639
79. Arora R, Thornblade CE, Dauby PA, Flanagan JW, Bush AC, Hagan LL. Exhaled nitric oxide levels in military recruits with new onset asthma. Allergy Asthma Proc 2006;27:493-8. http://dx.doi.org/10.2500/aap.2006.27.2904
80. Chancafe-Morgan J, Ramos-Quispe Y, Gomez-García R, Vargas-Espinal J, Puente-Maestú L. Validity of the fractional exhaled nitric oxide (FENO) for identification of bronchial hyperresponsiveness in a pulmonary function laboratory. Eur Respir J 2013;42(Suppl. 57):P1273.
81. Katsoulis K, Ganavias L, Michailopoulos P, Bikas C, Dinapogias E, Kontakiotis T, et al. Exhaled nitric oxide as screening tool in subjects with suspected asthma without reversibility. Int Arch Allergy Immunol 2013;162:58-64. http://dx.doi.org/10.1159/000350221
82. Heffler E, Guida G, Marsico P, Bergia R, Bommarito L, Ferrero N, et al. Exhaled nitric oxide as a diagnostic test for asthma in rhinitic patients with asthmatic symptoms. Respir Med 2006;100:1981-7. http://dx.doi.org/10.1016/j.rmed.2006.02.019
83. Smith AD, Cowan JO, Brassett KP, Filsell S, McLachlan C, Monti-Sheehan G, et al. Exhaled nitric oxide: a predictor of steroid response. Am J Respir Crit Care Med 2005;172:453-9. http://dx.doi.org/10.1164/rccm.200411-1498OC
84. de la Barra SL, Smith AD, Cowan JO, Herbison GP, Taylor DR. Predicted versus absolute values in the application of exhaled nitric oxide measurements. Respir Med 2011;105:1629-34. http://dx.doi.org/10.1016/j.rmed.2011.06.001
85. Pedrosa M, Cancelliere N, Barranco P, Lopez-Carrasco V, Quirce S. Usefulness of exhaled nitric oxide for diagnosing asthma. J Asthma 2010;47:817-21. http://dx.doi.org/10.3109/02770903.2010.491147
86. Smith AD, Cowan JO, Filsell S, McLachlan C, Monti-Sheehan G, Jackson P, et al. Diagnosing asthma: comparisons between exhaled nitric oxide measurements and conventional tests. Am J Respir Crit Care Med 2004;169:473-8. http://dx.doi.org/10.1164/rccm.200310-1376OC
87. Cordeiro D, Rudolphus A, Snoey E, Braunstahl G-J. Utility of nitric oxide for the diagnosis of asthma in an allergy clinic population. Allergy Asthma Proc 2011;32:119-26. http://dx.doi.org/10.2500/aap.2011.32.3419
88. Bobolea ID, Barranco P, Lopez-Carrasco V, Calderon O, Guillen D, Quirce S. Is methacholine challenge sufficient to rule out bronchial hyperresponsiveness in patients with suspected asthma? J Allergy Clin Immunol 2012;129(Suppl. 1):AB3. http://dx.doi.org/10.1016/j.jaci.2011.12.870
89. Zhang YM, Lin JT, Su N, Chen X, Liu GL, Yu HX, et al. [Values of fractional exhaled nitric oxide in the diagnosis of chronic cough]. Chung-Hua i Hsueh Tsa Chih 2011;91:1254-8.
90. Pizzimenti S, Heffler E, Piccioni P, Bugiani M, Migliore E, Guida G, et al. Usefulness of exhaled nitric oxide (FeNO) measured by a portable analyzer to diagnose cough variant asthma in a clinical setting of chronic cough. Allergy 2009;64:395.
91. Mathew S, Cliff I, Agarwal S, Lim A, Allen M, Mustfa N. Relationship between exhaled nitric oxide and methacholine challenge test in suspected asthma. Am J Respir Crit Care Med 2011;183. URL: http://ajrccm.atsjournals.org/cgi/reprint/183/1_MeetingAbstracts/A5554?sid=0209d9f3-c74d-409d-8e6e-81ebe76d2328 (accessed 19 May 2015).
92. Brannan JD, Adoni H, Daw L, Huang HC, Hurwitz M, Figurski D. Fraction exhaled NO in patients referred to pulmonary function laboratory (PFLAB) for mannitol challenge. Respirology 2013;18:43.
93. Linkosalo L, Lehtimaki L, Holm K, Kaila M, Moilanen E. Relation of bronchial and alveolar nitric oxide to exercise-induced bronchoconstriction in atopic children and adolescents. Pediatr Allergy Immunol 2012;23:360-6. http://dx.doi.org/10.1111/j.1399-3038.2011.01223.x
94. Ramser M, Hammer J, Amacher A, Trachsel D. The value of exhaled nitric oxide in predicting bronchial hyperresponsiveness in children. J Asthma 2008;45:191-5. http://dx.doi.org/10.1080/02770900801890273
95. Sivan Y, Gadish T, Fireman E, Soferman R. The use of exhaled nitric oxide in the diagnosis of asthma in school children. J Pediatr 2009;155:211-16. http://dx.doi.org/10.1016/j.jpeds.2009.02.034
96. Woo SI, Lee JH, Kim H, Kang JW, Sun YH, Hahn YS. Utility of fractional exhaled nitric oxide (FENO) measurements in diagnosing asthma. Respir Med 2012;106:1103-9. http://dx.doi.org/10.1016/j.rmed.2012.03.022
97. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005;352:2163-73. http://dx.doi.org/10.1056/NEJMoa043596
98. Shaw DE, Berry MA, Thomas M, Green RH, Brightling CE, Wardlaw AJ, et al. The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial. Am J Respir Crit Care Med 2007;176:231-7. http://dx.doi.org/10.1164/rccm.200610-1427OC
99. Syk J, Malinovschi A, Johansson G, Unden AL, Andreasson A, Lekander M, et al. Anti-inflammatory treatment of atopic asthma guided by exhaled nitric oxide: a randomized controlled trial. J Allergy Clin Immunol Pract 2013;1:639-48. http://dx.doi.org/10.1016/j.jaip.2013.07.013
100. Calhoun WJ, Ameredes BT, King TS, Icitovic N, Bleecker ER, Castro M, et al. Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial. JAMA 2012;308:987-97. http://dx.doi.org/10.1001/2012.jama.10893
101. Honkoop P, Loijmans R, Termeer E, Snoeck-Stroband J, Assendelft P, Sterk P, et al. A cluster randomized trial comparing strict, partial, and FeNO-guided asthma control strategies in primary care. Eur Respir J 2013;42(Suppl. 57):1710. http://dx.doi.org/10.1016/j.jaci.2014.07.016
102. Powell H, Murphy VE, Taylor DR, Hensley MJ, McCaffery K, Giles W, et al. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. Lancet 2011;378:983-90. http://dx.doi.org/10.1016/S0140-6736(11)60971-9
103. Fritsch M, Uxa S, Horak F Jr, Putschoegl B, Dehlink E, Szepfalusi Z, et al. Exhaled nitric oxide in the management of childhood asthma: a prospective 6-months study. Pediatr Pulmonol 2006;41:855-62. http://dx.doi.org/10.1002/ppul.20455
104. Szefler SJ, Mitchell H, Sorkness CA, Gergen PJ, O’Connor GT, Morgan WJ, et al. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. Lancet 2008;372:1065-72. http://dx.doi.org/10.1016/S0140-6736(08)61448-8
105. Verini M, Consilvio NP, Di Pillo S, Cingolani A, Spagnuolo C, Rapino D, et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. J Allergy 2010;2010:691425. http://dx.doi.org/10.1155/2010/691425
106. Pijnenburg MW, Bakker EM, Hop WC, de Jongste JC. Titrating steroids on exhaled nitric oxide in children with asthma: a randomized controlled trial. Am J Respir Crit Care Med 2005;172:831-6. http://dx.doi.org/10.1164/rccm.200503-458OC
107. Petsky H, Li AM, Kynaston JA, Turner C, Chang AB. Dual-center randomised trial on tailored asthma therapy based on exhaled nitric oxide (FENO) versus routine clinical care. Am J Respir Crit Care Med 2010;181:A3928. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a3928
108. Pike K, Selby A, Price S, Warner J, Connett G, Legg J, et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid dose in paediatric asthma: a randomised controlled trial. Clin Respir J 2013;7:204-13. http://dx.doi.org/10.1111/j.1752-699X.2012.00306.x
109. Peirsman EJ, Carvelli TJ, Hage PY, Hanssens LS, Pattyn L, Raes MM, et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial [published online ahead of print September 4 2013]. Pediatr Pulmonol 2013. http://dx.doi.org/10.1002/ppul.22873
110. Malinovschi A, Backer V, Harving H, Porsbjerg C. The value of exhaled nitric oxide to identify asthma in smoking patients with asthma-like symptoms. Respir Med 2012;106:794-801. http://dx.doi.org/10.1016/j.rmed.2012.02.009
111. Mahut B, Peyrard S, Delclaux C. Exhaled nitric oxide and clinical phenotypes of childhood asthma. Respir Res 2011;12:65. http://dx.doi.org/10.1186/1465-9921-12-65
112. Hanson J, DeLurgio S, Williams D, Dinakar C. Ambulatory fractional exhaled nitric oxide (FENO) measurement in children 4-7 years of age. Ann Allergy Asthma Immunol 2012;109:A22. http://dx.doi.org/10.1016/j.anai.2013.07.020
113. de la Riva-Velasco E, Krishnan S, Dozor AJ. Relationship between exhaled nitric oxide and exposure to low-level environmental tobacco smoke in children with asthma on inhaled corticosteroids. J Asthma 2012;49:673-8. http://dx.doi.org/10.3109/02770903.2012.701363
114. Tamasi L, Bohacs A, Bikov A, Andorka C, Rigo J Jr, Losonczy G, et al. Exhaled nitric oxide in pregnant healthy and asthmatic women. J Asthma 2009;46:786-91. http://dx.doi.org/10.1080/02770900903090004
115. Simpson JL, McDonald VM, Gibson PG. Exhaled nitric oxide is not a marker of eosinophilic inflammation in older Australians. Respirology 2010;15:A53. http://dx.doi.org/10.1111/crj.12017
116. Inoue H, Niimi A, Takeda T, Matsumoto H, Ito I, Otsuka K, et al. Pathophysiological characteristics of asthma in the elderly. Am J Respir Crit Care Med 2010;181:A5096. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a5096
117. Columbo M, Wong B, Panettieri RA, Rohr AS. Asthma in the elderly: the role of exhaled nitric oxide measurements. J Allergy Clin Immunol 2012;129(Suppl. 1):AB8. http://dx.doi.org/10.1016/j.jaci.2011.12.891
118. Roh YH. Usefulness of asthma control test questionnaire, FEV1 and exhaled nitric oxide level (FENO) for the clinical assessment of elderly asthma. World Allergy Organ J 2012;5:S160. http://dx.doi.org/10.1097/01.WOX.0000412212.37057.12
119. Smith AM, Villareal M, Bernstein DI, Swikert DJ. Asthma in the elderly: risk factors and impact on physical function. Ann Allergy Asthma Immunol 2012;108:305-10. http://dx.doi.org/10.1016/j.anai.2012.02.022
120. Ross J, Baptist A. Factors associated with asthma quality of life and control among older adults. Ann Allergy Asthma Immunol 2011;107(Suppl. 1):A5. http://dx.doi.org/10.1016/j.jaip.2012.12.003
121. Michils A, Louis R, Peche R, Baldassarre S, Van Muylem A. Exhaled nitric oxide as a marker of asthma control in smoking patients. Eur Respir J 2009;33:1295-301. http://dx.doi.org/10.1183/ 09031936.00154008
122. Kostikas K, Papaioannou AI, Tanou K, Giouleka P, Koutsokera A, Minas M, et al. Exhaled NO and exhaled breath condensate pH in the evaluation of asthma control. Respir Med 2011;105:526-32. http://dx.doi.org/10.1016/j.rmed.2010.10.015
123. Hromis S, Milutinov S, Zvezdin B, Kopitovic I, Maksimovic O. Exhaled nitric oxide in assessing of asthma control in smoking patients pilot study. Allergy 2012;67:461.
124. Mattes J, Murphy V, Powell H, Gibson P. The effect of better asthma control in pregnancy on wheezy illnesses in infancy. Respirology 2013;18:29.
125. Bozek A, Filipowski M, Fischer A, Jarzab J. Characteristics of atopic bronchial asthma in seniors over 80 years of age. Biomed Res Int 2013;2013:689-782. http://dx.doi.org/10.1155/2013/689782
126. Columbo M, Wong B, Panettieri RA Jr, Rohr AS. Asthma in the elderly: the role of exhaled nitric oxide measurements. Respir Med 2013;107:785-7. http://dx.doi.org/10.1016/j.rmed.2013.01.018
127. Olaguibel JM, Parra A, Alvarez MJ, Quirce S, Lopez R. Measurements of fractional exhaled nitric oxide with 2 portable electrochemical sensors: a comparative study. J Investig Allergol Clin Immunol 2011;21:322-3.
128. Bland M, Altman D. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;327:307-10. http://dx.doi.org/10.1016/S0140-6736(86)90837-8
129. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2007. URL: www.ginasthma.org (accessed 19 May 2015).
130. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987;136:225-35. http://dx.doi.org/10.1164/ajrccm/136.1.225
131. Whiting P, Rutjes A, Reitsma J, Bossuyt P, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003;3:25. http://dx.doi.org/10.1186/1471-2288-3-25
132. Asher M, Keil U, Anderson H, Beasley R, Crane J, Martinez F, et al. International Study of Asthma and Allergies in Childhood (ISAAC): rationale and methods. Eur Respir J 1995;8:483e91.
133. American Thoracic Society. Recommendations for standardized procedures for the on-line and off-line measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children - 1999. Am J Respir Crit Care Med 1999;160:2104-17. http://dx.doi.org/10.1164/ajrccm.160.6.ats8-99
134. National Asthma Education and Prevention Program Expert Panel. Report 3: Guidelines for the Diagnosis and Management of Asthma. Rockville, MD: National Heart, Lung, and Blood Institute; 2007.
135. Juniper EF, O’Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999;14:902-7. http://dx.doi.org/10.1034/j.1399-3003.1999.14d29.x
136. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. NHLBI/WHO Workshop Report 1995. Bethesda, MD: National Institutes of Health; 2002.
137. Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011;184:602-15. http://dx.doi.org/10.1164/rccm.9120-11ST.
138. Scott M, Raza A, Karmaus W, Mitchell F, Grundy J, Kurukulaaratchy RJ, et al. Influence of atopy and asthma on exhaled nitric oxide in an unselected birth cohort study. Thorax 2010;65:258-62. http://dx.doi.org/10.1136/thx.2009.125443
139. Frischer T, Eber E, Eichler I, Horak E, Riedler J, Gotz M, et al. Consensus guidelines for drug therapy of bronchial asthma in children and adolescents. Wien Klin Wochenschr 1999;111:900-2.
140. National Heart, Lung, and Blood Institute (NHLBI). National Asthma Education and Prevention Program. 2013. URL: www.nhlbi.nih.gov/about/org/naepp (accessed 15 July 2015).
141. Beck-Ripp J, Griese M, Arenz S, Koring C, Pasqualoni B, Bufler P, et al. Changes of exhaled nitric oxide during steroid treatment of childhood asthma. Eur Respir J 2002;19:1015-19. http://dx.doi.org/10.1183/09031936.02.01582001
142. Lehtimaki L, Turjanmaa V, Kankaanranta H, Saarelainen S, Hahtola P, Moilanen E. Increased bronchial nitric oxide production in patients with asthma measured with a novel method of different exhalation flow rates. Ann Med 2000;32:417-23. http://dx.doi.org/10.3109/07853890008995949
143. Medicines and Healthcare products Regulatory Agency. Asthma: Long-Acting Beta 2 Agonists: Reminder for Use in Children and Adults. URL: www.gov.uk/drug-safety-update/long-acting-2-agonists-reminder-for-use-in-children-and-adults (accessed 22 July 2015).
144. Drummond M, Sculpher M, Torrance G, O’Brien B, Stoddart G. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press; 2005.
145. National Institute for Health and Care Excellence. Diagnostics Assessment Programme Manual. Manchester: NICE; 2011.
146. Weinstein M, O’Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - Modeling Studies. Value Health 2003;6:9-17. http://dx.doi.org/10.1046/j.1524-4733.2003.00234.x
147. Price D, Berg J, Lindgren P. An economic evaluation of NIOX MINO airway inflammation monitor in the United Kingdom. Allergy 2009;64:431-8. http://dx.doi.org/10.1111/j.1398-9995.2008.01855.x
148. Berg J, Lindgren P. Economic evaluation of FE(NO) measurement in diagnosis and 1-year management of asthma in Germany. Respir Med 2008;102:219-31. http://dx.doi.org/10.1016/ j.rmed.2007.09.008
149. Peters J, Stevenson M, Beverley C, Lim JNW, Smith S. The clinical effectiveness and cost-effectiveness of inhaler devices used in the routine management of chronic asthma in older children: a systematic review and economic evaluation. Health Technol Assess 2002;6(5). http://dx.doi.org/10.3310/hta6050
150. Briggs AH, Bousquet J, Wallace MV, Busse WW, Clark TJ, Pedersen SE, et al. Cost-effectiveness of asthma control: an economic appraisal of the GOAL study. Allergy 2006;61:531-6. http://dx.doi.org/10.1111/j.1398-9995.2006.01038.x
151. Doull I, Price D, Thomas M, Hawkins N, Stamuli E, Tabberer M, et al. Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma. Curr Med Res Opin 2007;23:1147-59. http://dx.doi.org/10.1185/030079907X187982
152. Wilson EC, Price D, Musgrave SD, Sims EJ, Shepstone L, Murdoch J, et al. Cost-effectiveness of leukotriene receptor antagonists versus long-acting beta-2 agonists as add-on therapy to inhaled corticosteroids for asthma: a pragmatic trial. Pharmacoeconomics 2010;28:597-608. http://dx.doi.org/10.2165/11537550-000000000-00000
153. Paggiaro P, Buseghin G, Nicolini G, Patel S, Iannazzo S, Zaniolo O, et al. The cost-effectiveness of step down from high dose ICS/LABA combination therapy in asthma in the UK setting. Value Health 2011;14:A493-4. http://dx.doi.org/10.1016/j.jval.2011.08.1423
154. Booth PC, Capsey LJ, Langdon CG, Wells NEJ. A comparison of the cost-effectiveness of alternative prophylactic therapies in the treatment of adult asthma. Br J Med Econ 1995;8:65-72.
155. Barnes NC, Thwaites RM, Price MJ. The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children. Respir Med 1999;93:402-7. http://dx.doi.org/10.1053/rmed.1999.0577
156. Payne DN, Qiu Y, Zhu J, Peachey L, Scallan M, Bush A, et al. Airway inflammation in children with difficult asthma: relationships with airflow limitation and persistent symptoms. Thorax 2004;59:862-9. http://dx.doi.org/10.1136/thx.2003.017244
157. Everden P, Lloyd A, Hutchinson J, Plumb J. Cost-effectiveness of eformoterol Turbohaler versus salmeterol Accuhaler in children with symptomatic asthma. Respir Med 2002;96:250-8. http://dx.doi.org/10.1053/rmed.2001.1258
158. Price MJ, Briggs AH. Development of an economic model to assess the cost-effectiveness of asthma management strategies. Pharmacoeconomics 2002;20:183-94. http://dx.doi.org/10.2165/00019053-200220030-00004
159. Buxton MJ, Sullivan SD, Andersson LF, Lamm CJ, Liljas B, Busse WW, et al. Country-specific cost-effectiveness of early intervention with budesonide in mild asthma. Eur Respir J 2004;24:568-74. http://dx.doi.org/10.1183/09031936.04.00108703
160. Price D, Wiren A, Kuna P. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy 2007;62:1189-98. http://dx.doi.org/10.1111/j.1398-9995.2007.01466.x
161. Kemp L, Haughney J, Barnes N, Sims E, Von ZJ, Hillyer EV, et al. Cost-effectiveness analysis of corticosteroid inhaler devices in primary care asthma management: a real world observational study. Clinicoecon Outcomes Res 2010;2:75-85.
162. Smith AD, Taylor DR. Is exhaled nitric oxide measurement a useful clinical test in asthma? Curr Opin Allergy Clin Immunol 2005;5:49-56. http://dx.doi.org/10.1097/00130832-200502000-00010
163. Hunter C, Brightling C, Woltmann G, Wardlow A, Pavord I. A comparison of the validity of different diagnostic tests in adults with asthma. Chest 2002;121:1051-7. http://dx.doi.org/10.1378/chest.121.4.1051
164. British Thoracic Society and Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma, 2007 update. Edinburgh and London: BTS/SIGN; 2007.
165. Department of Health. NHS Reference Costs 2005. London: Department of Health; 2005.
166. Curtis L, Netten A. Unit Costs of Health and Social Care 2005. Canterbury: Personal Social Services Research Unit, University of Kent; 2005.
167. Joint Formulary Committee. British National Formulary. 51 ed. London: BMJ Group and Pharmaceutical Press; 2006.
168. Dupont LJ, Demedts MG, Verleden GM. Prospective evaluation of the validity of exhaled nitric oxide for the diagnosis of asthma. Chest 2003;123:751-6. http://dx.doi.org/10.1378/chest.123.3.751
169. Jayaram L, Pizzichini MM, Cook RJ, Boulet LP, LemiÇùre C, Pizzichini E, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006;27:483-94. http://dx.doi.org/10.1183/09031936.06.00137704.
170. Andersson F, Stahl E, Barnes PJ, LÇôfdahl CG, O’Byrne PM, Pauwels RA, et al. Adding formoterol to budesonide in moderate asthma - health economic results from the FACET study. Respir Med 2001;95:505-12. http://dx.doi.org/10.1053/rmed.2001.1078
171. Tattersfield AE, Postma DS, Barnes PJ, Svensson K, Bauer CA, O’Byrne PM, et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med 1999;160:594-9. http://dx.doi.org/10.1164/ajrccm.160.2.9811100
172. Szende A, Svensson K, Stahl E, Meszaros A, Berta GY. Psychometric and utility-based measures of health status of asthmatic patients with different disease control level. Pharmacoeconomics 2004;22:537-47. http://dx.doi.org/10.2165/00019053-200422080-00005
173. Akinbami L, Moorman J, Liu X. Asthma Prevalence, Health Care Use, and Mortality: United States, 2005-2009. National Health Statistics Reports 12 January 2011, no. 32. URL: www.cdc.gov/nchs/data/nhsr/nhsr032.pdf (accessed 19 May 2015).
174. Department of Health. NHS Reference Costs 2011-12. London: Department of Health; 2012.
175. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998;316:736-41. http://dx.doi.org/10.1136/bmj.316.7133.736
176. Piacentini GL, Peroni DG, Bonafiglia E, Chinellato I, Bodini A, Boner AL. Childhood asthma control test (C-ACT) and nasal eosinophil inflammation in asthmatic children. Allergy 2010;65:796-7. http://dx.doi.org/10.1111/j.1398-9995.2009.02237.x
177. Andersson F, Borg S, Barnes PJ, Lofdahl CG, O’Byrne P, Postma D, et al. A high dose of inhaled budesonide is more cost-effective than a low dose in moderate asthma. J Allergy Clin Immunol 2000;105:S102-3. http://dx.doi.org/10.1016/S0091-6749(00)90734-6
178. British Thoracic Society/Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma. Revised edn. Edinburgh and London: BTS/SIGN; November 2005.
179. Curtis L. Unit Costs of Health and Social Care 2012. Canterbury: Personal Social Services Research Unit, University of Kent; 2012.
180. Main C, Shepherd J, Anderson R, Rogers G, Thompson Coon J, Liu Z, et al. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in children under the age of 12 years. Health Technol Assess 2008;12(20). http://dx.doi.org/10.3310/hta12200
181. McTaggart-Cowan H, Marra C, Yang Y, Brazier J, Kopec J, FitzGerald J, et al. The validity of generic and condition-specific preference-based instruments: the ability to discriminate asthma control status. Qual Life Res 2008;17:453-62. http://dx.doi.org/10.1007/s11136-008-9309-6
182. Sullivan P, Slejko J, Sculpher MJ, Ghushchyan V. Catalogue of EQ-5D scores for the United Kingdom. Med Decis Making 2011;31:800-4. http://dx.doi.org/10.1177/0272989X11401031
183. Ara R, Brazier JE. Populating an economic model with health state utility values: moving toward better practice. Value Health 2010;13:509-18. http://dx.doi.org/10.1111/j.1524-4733.2010.00700.x
184. Lloyd A, Price D, Brown R. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Respir J 2007;16:22-7. http://dx.doi.org/10.3132/pcrj.2007.00002
185. Joint Formulary Committee. British National Formulary. 65 ed. London: BMJ Group and Pharmaceutical Press; 2013.
186. Davis S. A Review of the Psychometric Performance of the EQ-5D in Patients with Asthma. Report prepared for NICE by the Decision Support Unit. Sheffield: University of Sheffield; 2010.
187. National Institute for Health and Care Excellence. Inhaled Corticosteroids for the Treatment of Chronic Asthma in Children under the Age of 12 Years. Technology appraisal guidance 131. London: NICE; 2007.
188. National Institute for Health and Care Excellence. Inhaled Corticosteroids for the Treatment of Chronic Asthma in Adults and in Children aged 12 Years and Over. Technology appraisal guidance 138. London: NICE; 2008.
189. Office for National Statistics. Interim Life Tables, England and Wales, 2009-2011. London: ONS; 2011. URL: www.ons.gov.uk/ons/rel/lifetables/interim-life-tables/2009-2011/stb-2009-2011.html (accessed 22 July 2015).
190. de Jongste JC, Carraro S, Hop WC, CHARISM Study Group, Baraldi E. Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. Am J Respir Crit Care Med 2009;179:93-7. http://dx.doi.org/10.1164/rccm.200807-1010OC
191. Donohue JF, Jain N. Exhaled nitric oxide to predict corticosteroid responsiveness and reduce asthma exacerbation rates. Respir Med 2013;107:943-52. http://dx.doi.org/10.1016/j.rmed.2013.02.018
192. Tan KS, Thomson NC. Asthma in pregnancy. Am J Med 2000;109:727x-33. http://dx.doi.org/10.1016/S0002-9343(00)00615-X
193. Moher D, Liberati A, Tetzlaff J, Altman D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Med 2009;6:e1000097. http://dx.doi.org/10.1371/journal.pmed.1000097